Navigation Links
Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
Date:4/17/2008

sruptive technologies; reimbursement policies of government agencies and private payers; the availability of acceptable raw materials and component supply; the ability to enforce company patents; patents of third parties preventing or restricting the company's manufacture, sale or use of affected products or technology; foreign currency fluctuations and other risks identified in the company's most recent filing on Form 10-K and other Securities and Exchange Commission filings, all of which are available on the company's website. The company does not undertake to update its forward-looking statements. Financial schedules are attached to this release and available on the company's website.

BAXTER INTERNATIONAL INC.

Consolidated Statements of Income

Three Months Ended March 31, 2008 and 2007

(unaudited)

(in millions, except per share and percentage data)

Three Months Ended

March 31,

--------------------

2008 2007 Change

------- ------- --------

NET SALES $2,877 $2,675 8%

COST OF GOODS SOLD 1,497 (1) 1,409 6%

------------------------------------------------------------------------

GROSS PROFIT 1,380 1,266 9%

------------------------------------------------------------------------

% of Sales 48.0% 47.3% 0.7 pts

MARKETING AND ADMINISTRATIVE EXPENSES 640 583 10%

% of Sales 22.2% 21.8% 0.4 pts

RESE
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
2. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
3. Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year
4. Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
5. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
6. Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
7. Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular Technology
8. Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit
9. Baxter International Fourth Quarter 2007 Financial Results Conference Call
10. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
11. Baxters Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be ... Miami, FL on March 10, 2015 at ... Chief Financial Officer, will provide a corporate overview. ... Halozyme,s corporate website at www.halozyme.com , and a recording ... To access the live webcast, please log on to Halozyme,s ...
(Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... "Gene Therapy Market, 2015 - 2025" report ... Market, 2015-2025" report provides an extensive study on the ... has been carried out in this field for over ... (four available in Asian markets; one approved in the ...
(Date:3/3/2015)... BlueInGreen announces the ... sales network. The business venture will bring the ... Atlantic Provinces, exclusively through Resource Systems. , Since ... Canada’s premiere manufacturing representative firms, hosting a diverse ... and wastewater markets. More information on Resource Systems ...
(Date:3/3/2015)... March 03, 2015 The winners of ... were honored by the Global Supply Chain Resiliency ... took place on Wednesday, February 25th, 2015, at the ... was formed to bring together supply chain risk management ... advance the professional discipline through opportunities to collaborate, develop ...
Breaking Biology Technology:Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7BlueInGreen® Continues Canadian Expansion, Partners with Resource Systems Inc. 2Global Supply Chain Resiliency Council Names Award Winners 2Global Supply Chain Resiliency Council Names Award Winners 3Global Supply Chain Resiliency Council Names Award Winners 4
... MYL ) today announced its financial results for the three and ... Adjusted diluted EPS of $0.55 for the three ... year period; Adjusted diluted EPS of $1.51 for the ... prior year period; Total revenues of $1.58 billion for ...
... of recent salmonella outbreaks in the United States: ground ... and the list goes on, according to the U.S. ... for long, thanks to a promising new biosensor nanotechnology ... contaminated food or animals reach the marketplace. In the ...
... Inc. (Nasdaq: SGMO ) today reported third quarter ... third quarter ended September 30, 2011, Sangamo reported a consolidated ... to a net loss of $8.7 million, or $0.19 per ... 30, 2011, the Company had cash, cash equivalents and marketable ...
Cached Biology Technology:Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 2Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 3Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 4Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 5Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 6Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 7Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 8Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 9Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 10Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 11Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 12Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 13Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 14Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 15Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55 16Sangamo BioSciences Reports Third Quarter 2011 Financial Results 2Sangamo BioSciences Reports Third Quarter 2011 Financial Results 3Sangamo BioSciences Reports Third Quarter 2011 Financial Results 4Sangamo BioSciences Reports Third Quarter 2011 Financial Results 5Sangamo BioSciences Reports Third Quarter 2011 Financial Results 6
(Date:2/10/2015)... Feb. 10, 2015  Alere Inc. (NYSE: ALR), ... financial results for the quarter ended December 31, ... and President of Alere said, "We made substantial ... as the global leader in rapid diagnostics and ... Alere Health divestiture in early January enabled us ...
(Date:2/5/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... ) as part of its 2015 marketing and branding ... its new consumer website for Wocketwallet.com earlier this month. ... NXT-ID said, "Our new corporate website naturally showcases our ...
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying ... power and potential for genomic science as a means ... disease prevention and treatment.  I was honored to participate ... government-funded precision medicine program. Since the ... science of genomics—from the first sequenced genome of a ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... Office has granted an exclusive license of a novel ... Inc., which plans to initiate early-stage human clinical trials ... Gary Landreth, PhD, the Riuko and Archie G. Co ... PhD, co-founded ReXceptor after discovering that bexarotene (a medication ...
... and Oxford, UK Cancer cells are a problem for ... blithely metastasize to set up shop in places where they ... this way is a tumor suppressor named p53. This protein ... those that are damaged beyond repair. Not surprisingly, p53,s critical ...
... across the UK has shown a grass hybrid species ... The BBSRC-funded scientists, from Rothamsted Research, the James Hutton ... at Aberystwyth University, Lancaster University and the University of ... perennial ryegrass ( Lolium perenne ) with a closely ...
Cached Biology News:Research spinoff ReXceptor gets license for Alzheimer's treatment 2Reviving a foe of cancer 2New grass hybrid could help reduce the likelihood of flooding 2
... mat made from an inert polymer with a ... 384 split septum caps for use with ... for PCR when used in conjunction with screw ... with standard pipetting equipment 384 septum caps ...
... unique alternative to traditional TBE (TRIS ... buffers. Bionic Buffer allows for higher ... and high-resolution band separation. -Application: Ready ... dilution to working 1x concentrations. ...
The Mu-End™ Protein Truncation Kit provides a convenient method for generating a library of N-terminal and C-terminal protein deletions that can be expressed in E. coli....
... IR Mouse Cytokine Array is a multiplex ... quantitative measurement of 12 cytokines in serum; ... supernatants. Each well of the microplate provided ... cytokines in standards and samples added to ...
Biology Products: